SCHEMBL5630355

SCHEMBL5630355

O=C(O)NC[C@H](O)CNS(=O)(=O)c1ccccn1

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.50
KAT6A Q92794 1/20 0.48
METAP2 P50579 1/20 0.44
CTSK P43235 2/20 0.42
KMT2A Q03164 2/20 0.40
MEN1 O00255 1/20 0.40
MAPT P10636 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
MMP2 P08253 3/20 0.39
PKM P14618 1/20 0.39
GLO1 Q04760 2/20 0.37
ALDH1A1 P00352 1/20 0.37
SLC40A1 Q9NP59 1/20 0.37
GBA1 P04062 1/20 0.37
NLRP3 Q96P20 1/20 0.37
PTGS2 P35354 1/20 0.37
HTT P42858 1/20 0.36
ATM Q13315 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5632717 1.00 L3MBTL1 (0.50) L3MBTL1KAT6AMETAP2CTSKKMT2A
SCHEMBL5632090 0.82 L3MBTL1 (0.43) L3MBTL1KAT6AMETAP2CTSKKMT2A
SCHEMBL455967 0.80 L3MBTL1 (0.55) L3MBTL1KAT6AMETAP2CTSKKMT2A
SCHEMBL6622127 0.80 CTSK (0.47) L3MBTL1KAT6ACTSKALDH1A1
SCHEMBL5631694 0.78 L3MBTL1 (0.50) L3MBTL1KAT6AMETAP2CTSKKMT2A
SCHEMBL5631689 0.78 L3MBTL1 (0.50) L3MBTL1KAT6AMETAP2CTSKKMT2A
SCHEMBL7468216 0.75 CTSK (0.53) CTSKSMN1; SMN2ALDH1A1HTT
SCHEMBL10438614 0.75 KAT6A (0.63) L3MBTL1KAT6AMETAP2CTSKKMT2A
Hydrochloric Acid SCHEMBL5631844 0.73 L3MBTL1 (0.54) L3MBTL1KAT6AMETAP2CTSKKMT2A
Hydrochloric Acid SCHEMBL5631436 0.73 L3MBTL1 (0.54) L3MBTL1KAT6AMETAP2CTSKKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7288541-B2 Propylcarbamate derivatives as inhibitors of serine and cysteine proteases SMITHKLINE BEECHAM CORPORATION (US) 2007-10-30 US disclosed
US-20050043368-A1 Propylcarbamate derivatives as inhibitors of serine and cysteine proteases SMITHKLINE BEECHAM CORPORATION 2005-02-24 US disclosed
EP-1448554-A1 PROPYLCARBAMATE DERIVATIVES AS INHIBITORS OF SERINE AND CYSTEINE PROTEASES SmithKline Beecham Corporation (US) 2004-08-25 EP disclosed
WO-2003031437-A1 PROPYLCARBAMATE DERIVATIVES AS INHIBITORS OF SERINE AND CYSTEINE PROTEASES SMITHKLINE BEECHAM CORPORATION (US) 2003-04-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050043368-A1 Propylcarbamate derivatives as inhibitors of serine and cysteine proteases CTSK, CTSB, CTSS L3MBTL1 1234/4885KAT6A 2379/4885METAP2 509/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.